NASDAQ:WVE Wave Life Sciences (WVE) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free WVE Stock Alerts $4.84 -0.03 (-0.62%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$4.64▼$4.9450-Day Range$3.54▼$6.8452-Week Range$3.15▼$7.67Volume492,475 shsAverage Volume511,950 shsMarket Capitalization$591.84 millionP/E RatioN/ADividend YieldN/APrice Target$10.14 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Wave Life Sciences alerts: Email Address Wave Life Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside109.6% Upside$10.14 Price TargetShort InterestBearish2.94% of Shares Sold ShortDividend StrengthN/ASustainability-0.58Upright™ Environmental ScoreNews Sentiment0.21Based on 6 Articles This WeekInsider TradingSelling Shares$96,437 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.94) to ($1.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.11 out of 5 starsMedical Sector157th out of 909 stocksPharmaceutical Preparations Industry58th out of 420 stocks 3.4 Analyst's Opinion Consensus RatingWave Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageWave Life Sciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.94% of the outstanding shares of Wave Life Sciences have been sold short.Short Interest Ratio / Days to CoverWave Life Sciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Wave Life Sciences has recently increased by 19.67%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldWave Life Sciences does not currently pay a dividend.Dividend GrowthWave Life Sciences does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreWave Life Sciences has received a 77.37% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Wave Life Sciences is -0.58. Previous Next 2.3 News and Social Media Coverage News SentimentWave Life Sciences has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Wave Life Sciences this week, compared to 2 articles on an average week.MarketBeat Follows5 people have added Wave Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Wave Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $96,437.00 in company stock.Percentage Held by Insiders31.10% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.73% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Wave Life Sciences are expected to decrease in the coming year, from ($0.94) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Wave Life Sciences is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Wave Life Sciences is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWave Life Sciences has a P/B Ratio of 12.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Wave Life Sciences Stock (NASDAQ:WVE)Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.Read More WVE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart WVE Stock News HeadlinesApril 7, 2024 | insidertrades.comKyle Moran Sells 15,630 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) StockApril 21, 2024 | americanbankingnews.comWave Life Sciences (NASDAQ:WVE) Shares Up 4.2%April 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 20, 2024 | investing.comWave Life Sciences Ltd (WVE)April 20, 2024 | yahoo.comSurfer Rides 93.73 Foot Wave. New Record for Biggest Ever?April 16, 2024 | money.usnews.comWave Life Sciences Ltd.April 13, 2024 | morningstar.comWAVE Life Sciences LtdApril 7, 2024 | investing.comWave Life Sciences CFO sells shares worth over $96kApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 4, 2024 | yahoo.com100 Foot Wave Season 1 Streaming: Watch & Stream Online via HBO MaxApril 1, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Wave Life Sciences (WVE)March 27, 2024 | globenewswire.comWave Life Sciences to Present at Upcoming Investor ConferencesMarch 23, 2024 | finance.yahoo.comBillionaire Paul Tudor Jones and Insiders Love These 10 StocksMarch 15, 2024 | msn.comWind and wave observations reveal the seasonal variations in wave-induced stress over global oceanMarch 9, 2024 | finance.yahoo.comWave Life Sciences Ltd. (NASDAQ:WVE) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesMarch 8, 2024 | seekingalpha.comWave Life Sciences' Weighty Ambition: Carving Out Obesity NicheMarch 8, 2024 | seekingalpha.comWave Life Sciences Ltd. (WVE) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comWave Life Sciences Ltd. (NASDAQ:WVE) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | marketwatch.comWave Life Sciences Shares Rise 31% After Narrower-Than-Expected 4Q LossMarch 6, 2024 | msn.comWave Life Sciences GAAP EPS of -$0.15 beats by $0.08, revenue of $29.06M beats by $9.23MMarch 6, 2024 | washingtonpost.comWave Life Sciences: Q4 Earnings SnapshotMarch 6, 2024 | markets.businessinsider.comWave Life Sciences Gains 34% On Narrower Loss In Q4March 6, 2024 | globenewswire.comWave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 5, 2024 | msn.comWave Life Sciences Q4 2023 Earnings PreviewMarch 2, 2024 | finance.yahoo.comWave Life Sciences Ltd. (WVE)February 28, 2024 | globenewswire.comWave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024February 27, 2024 | msn.comWas the 100 Foot Wave Surfed? A Semi-Scientific Breakdown (Clip)See More Headlines Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today4/23/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:WVE CUSIPN/A CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees266Year FoundedN/APrice Target and Rating Average Stock Price Target$10.14 High Stock Price Target$17.00 Low Stock Price Target$5.00 Potential Upside/Downside+109.6%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,510,000.00 Net Margins-50.76% Pretax Margin-51.36% Return on EquityN/A Return on Assets-23.67% Debt Debt-to-Equity RatioN/A Current Ratio1.26 Quick Ratio1.26 Sales & Book Value Annual Sales$113.31 million Price / Sales5.22 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book12.10Miscellaneous Outstanding Shares122,280,000Free Float84,254,000Market Cap$591.84 million OptionableOptionable Beta-1.13 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Paul B. Bolno M.B.A. (Age 50)M.D., President, CEO & Director Comp: $1.1MMr. Kyle B. Moran CFA (Age 53)CFO & Principal Accounting Officer Comp: $677.87kDr. Chandra Vargeese Ph.D. (Age 63)Chief Technology Officer Comp: $710.05kKate RauschHead of Investor RelationsMs. Linda Rockett J.D.Senior VP & General CounselDr. Christopher Francis Ph.D. (Age 46)Senior VP of Corporate Development & Head of Emerging Areas Comp: $493.13kMs. Daryn LewisSenior VP & Head of Human ResourcesDr. Sridhar Vaddeboina Ph.D.Senior Vice President of Chemistry, Manufacturing & ControlsMs. Anne-Marie Li-Kwai-CheungChief Development OfficerDr. Hsiu-Chiung Yang Ph.D.Senior Vice President of Translational MedicineMore ExecutivesKey CompetitorsCogent BiosciencesNASDAQ:COGTDianthus TherapeuticsNASDAQ:DNTHStoke TherapeuticsNASDAQ:STOKGracell BiotechnologiesNASDAQ:GRCLCelcuityNASDAQ:CELCView All CompetitorsInsiders & InstitutionsKyle MoranSold 15,630 sharesTotal: $96,437.10 ($6.17/share)Wellington Management Group LLPBought 9,208 shares on 3/5/2024Ownership: 0.277%Virtu Financial LLCBought 34,432 shares on 2/26/2024Ownership: 0.035%Public Employees Retirement System of OhioBought 12,600 shares on 2/16/2024Ownership: 0.013%Birchview Capital LPBought 40,000 shares on 2/15/2024Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions WVE Stock Analysis - Frequently Asked Questions Should I buy or sell Wave Life Sciences stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" WVE shares. View WVE analyst ratings or view top-rated stocks. What is Wave Life Sciences' stock price target for 2024? 7 brokerages have issued 1 year price objectives for Wave Life Sciences' shares. Their WVE share price targets range from $5.00 to $17.00. On average, they anticipate the company's stock price to reach $10.14 in the next year. This suggests a possible upside of 109.6% from the stock's current price. View analysts price targets for WVE or view top-rated stocks among Wall Street analysts. How have WVE shares performed in 2024? Wave Life Sciences' stock was trading at $5.05 on January 1st, 2024. Since then, WVE shares have decreased by 4.2% and is now trading at $4.84. View the best growth stocks for 2024 here. When is Wave Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our WVE earnings forecast. How were Wave Life Sciences' earnings last quarter? Wave Life Sciences Ltd. (NASDAQ:WVE) issued its earnings results on Wednesday, March, 6th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.04. The business had revenue of $29.06 million for the quarter, compared to the consensus estimate of $23.30 million. During the same period last year, the business earned ($0.47) EPS. What ETFs hold Wave Life Sciences' stock? ETFs with the largest weight of Wave Life Sciences (NASDAQ:WVE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Nasdaq Future Gen 200 ETF (QQQS). What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO? 17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Wave Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN). How do I buy shares of Wave Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:WVE) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Wave Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
